Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01389
|
|||||
| Drug Name |
Tyramine
|
|||||
| Synonyms |
Tyramine; 4-(2-Aminoethyl)phenol; 51-67-2; 4-Hydroxyphenethylamine; p-Tyramine; 2-(4-Hydroxyphenyl)ethylamine; Uteramine; Tyramin; Tyrosamine; Tocosine; 4-Hydroxyphenylethylamine; Systogene; Phenol, 4-(2-aminoethyl)-; p-Hydroxyphenethylamine; Tenosin-wirkstoff; p-Hydroxyphenylethylamine; p-(2-Aminoethyl)phenol; 2-(p-Hydroxyphenyl)ethylamine; Phenethylamine, p-hydroxy-; p-beta-Aminoethylphenol; Phenol, p-(2-aminoethyl)-; Benzeneethanamine, 4-hydroxy-; Tyramine base; beta-Hydroxyphenylethylamine; NSC 249188; p-tyramine; [3H]tyramine
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Parkinson's Disease [ICD11:8A00.0] | Phase 3 | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C8H11NO
|
|||||
| Canonical SMILES |
C1=CC(=CC=C1CCN)O
|
|||||
| InChI |
InChI=1S/C8H11NO/c9-6-5-7-1-3-8(10)4-2-7/h1-4,10H,5-6,9H2
|
|||||
| InChIKey |
DZGWFCGJZKJUFP-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 51-67-2
|
|||||
| Pharmaceutical Properties | Molecular Weight | 137.18 | Topological Polar Surface Area | 46.2 | ||
| Heavy Atom Count | 10 | Rotatable Bond Count | 2 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 2 | |||
| XLogP |
1.1
|
|||||
| PubChem CID | ||||||
| PubChem SID |
3766
,136967
,608127
,839997
,858070
,3134838
,5502075
,8143353
,8150088
,8153454
,10524949
,11111872
,11336093
,11361332
,11364107
,11366669
,11369231
,11371765
,11375541
,11377393
,11462304
,11484432
,11488554
,11490509
,11493615
,11495027
,15321440
,24715053
,24889929
,24900582
,25622217
,26512235
,26613119
,26679249
,26747190
,26747191
,26752293
,26752294
,29204652
,29224648
,41530225
,47291202
,47365262
,47515377
,47810820
,47959828
,47959829
,48035206
,49649954
,49748652
|
|||||
| ChEBI ID |
CHEBI:15760
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | 1-Oct | Transporter Info | Organic cation transporter 1 | Substrate | [2] | |
| References | ||||||
| 1 | ClinicalTrials.gov (NCT00203125) A Study to Evaluate the Effects of Tyramine in Patients Who Completed the PRESTO Study. | |||||
| 2 | Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.